Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 1:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 3,675 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Excision Clear all
Active, not recruiting Phase 1 Interventional Results available

Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma

NCT02208362
View directory record Official record
Conditions
Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma, Refractory Glioblastoma, Refractory Malignant Glioma, Refractory WHO Grade II Glioma, Refractory WHO Grade III Glioma
Interventions
Arm 1: IL13Ra2-specific CAR Tcm cells, Arm 2: IL13Ra2-specific CAR Tcm cells, Arm 3: IL13Ra2-specific CAR Tcm cells, Arm 4: IL13Ra2-specific CAR Tcm cells, Arm 5: IL13Ra2-specific CAR Tn/mem cells, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance Spectroscopic Imaging, Quality-of-Life Assessment
Biological · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
12 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 19, 2026, 1:58 AM EDT
Completed Phase 1 Interventional

Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma

NCT01811992
View directory record Official record
Conditions
Malignant Glioma, Glioblastoma Multiforme
Interventions
Dose Escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L
Biological
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 19, 2026, 1:58 AM EDT
Recruiting Not applicable Interventional

Forceps vs. Snare IVC Filter Removal

NCT04092192
View directory record Official record
Conditions
DVT
Interventions
IVC filter removal
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 19, 2026, 1:58 AM EDT
Active, not recruiting Early Phase 1 Interventional

Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients

NCT02933736
View directory record Official record
Conditions
Glioblastoma Multiforme, Meningioma
Interventions
Ribociclib
Drug
Lead sponsor
Nader Sanai
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 19, 2026, 1:58 AM EDT
Completed Not applicable Interventional

Trigger Finger Trial

NCT05251428
View directory record Official record
Conditions
Trigger Finger
Interventions
Excision of the A1 pulley, Incision of the A1 pulley in the standard fashion
Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 19, 2026, 1:58 AM EDT
Terminated Not applicable Interventional Results available

Diabetic Foot Infection Antibiotic Study

NCT01539811
View directory record Official record
Conditions
Diabetic Foot Infections
Interventions
Surgical incision and drainage of diabetic foot infection, Short course antibiotics, Long course antibiotics
Procedure · Drug
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 19, 2026, 1:58 AM EDT
Withdrawn Phase 2 Interventional

Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer

NCT05456165
View directory record Official record
Conditions
Colonic Neoplasms, Colorectal Neoplasms
Interventions
GRT-C901, GRT-R902, Atezolizumab, Ipilimumab, Adjuvant chemotherapy
Drug
Lead sponsor
Gritstone bio, Inc.
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Detroit, Michigan • New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Oct 19, 2026, 1:58 AM EDT
Completed Not applicable Interventional

Immediate Vaginal Reconstruction After Oncologic Resection: Surgical Outcomes, Patient Satisfaction and Sexual Function

NCT00588081
View directory record Official record
Conditions
Vaginal Cancer
Interventions
QOL
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 19, 2026, 1:58 AM EDT
Recruiting Not applicable Interventional

A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning

NCT06387485
View directory record Official record
Conditions
Sarcoma, Ewing, Chondrosarcoma, Osteosarcoma, Fibrous Histiocytoma, Fibrosarcoma
Interventions
3D Printed Anatomic Model, CT/MRI
Device · Diagnostic Test
Lead sponsor
Ricoh USA, Inc.
Industry
Eligibility
13 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Oakland, California • Royal Oak, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 19, 2026, 1:58 AM EDT
Withdrawn Phase 3 Interventional

Gabapentin for the Reduction of Opiate Use Following Pulmonary Resection (GROUP Trial)

NCT05100160
View directory record Official record
Conditions
Thoracic, Pulmonary Disease
Interventions
Gabapentin, Placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 19, 2026, 1:58 AM EDT
Recruiting Phase 2 Interventional

MOHs Surgery and Short-Course Radiation Therapy With Structured Follow-Up for Head & Neck Squamous Cell Skin Cancer

NCT06998342
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma (CSCC)
Interventions
Short course radiation, Active Surveillance
Radiation · Other
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 19, 2026, 1:58 AM EDT
Recruiting Not applicable Interventional

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

NCT03860883
View directory record Official record
Conditions
Cutaneous Melanoma, Stage II
Interventions
Wide Local Excision = 1cm Margin, Wide Local Excision = 2cm Margin
Procedure
Lead sponsor
Melanoma and Skin Cancer Trials Limited
Other
Eligibility
18 Years and older
Enrollment
2,998 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2034
U.S. locations
128
States / cities
Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 99 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 19, 2026, 1:58 AM EDT
Completed Phase 2 Interventional Results available

Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

NCT02427841
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma
Interventions
Fluorouracil, Gemcitabine, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Nab-paclitaxel, Therapeutic Conventional Surgery
Drug · Radiation · Other + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 19, 2026, 1:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Randomized Comparison of Transcervical Foley Bulb With Vaginal Misoprostol to Vaginal Misoprostol Alone for Induction of Labor

NCT02566005
View directory record Official record
Conditions
Pregnancy
Interventions
misoprostol, Foley bulb
Device
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2018 · Synced Oct 19, 2026, 1:58 AM EDT
Terminated Phase 2 Interventional Results available

AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites

NCT02417753
View directory record Official record
Conditions
Ovarian Cancer, Ovarian Neoplasms, Ascites, Gastrointestinal Cancer, Gastrointestinal Neoplasms
Interventions
AZD9150
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 19, 2026, 1:58 AM EDT
Not listed Phase 2 Interventional

Removal of Endotracheal Tube Secretions Comprehensively Until Extubation

NCT00663637
View directory record Official record
Conditions
Mechanical Ventilation, Pneumonia
Interventions
CAM (Complete Airway Management) Catheters
Device
Lead sponsor
O. M. Neotech, Inc.
Industry
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Cape Girardeau, Missouri
Source: ClinicalTrials.gov public record
Updated May 29, 2008 · Synced Oct 19, 2026, 1:58 AM EDT
Terminated Not applicable Interventional Results available

Use of Compression Glove to Prevent Complications After Distal Radius Fractures: a Randomized Controlled Trial

NCT01118715
View directory record Official record
Conditions
Post-traumatic Carpal Tunnel Syndrome, Complex Regional Pain Syndrome, Edema
Interventions
Compression glove
Device
Lead sponsor
J&M Shuler
Industry
Eligibility
18 Years to 85 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 19, 2026, 1:58 AM EDT
Completed Not applicable Interventional Results available

SBRT for Close or Positive Margins After Resection of Pancreatic Adenocarcinoma

NCT01357525
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas
Interventions
Stereotactic Body Radiation Therapy (SBRT)
Radiation
Lead sponsor
David A. Clump, MD, PhD
Other
Eligibility
18 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 19, 2026, 1:58 AM EDT
Completed Phase 2 Interventional Results available

Autologous Tumor Infiltrating Lymphocytes in Patients With Pretreated Metastatic Triple Negative Breast Cancer

NCT04111510
View directory record Official record
Conditions
Metastatic Triple Negative Breast Cancer
Interventions
Tumor infiltrating lymphocytes (TIL) LN-145
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 19, 2026, 1:58 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone

NCT02736123
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab - Arm A, Nivolumab + Ipilimumab - Arm B
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Oct 19, 2026, 1:58 AM EDT
Terminated Early Phase 1 Interventional

Liposomal Bupivacaine (Exparel) in Sarcomas

NCT03867188
View directory record Official record
Conditions
Soft Tissue Sarcoma, Soft Tissue Tumor, Soft Tissue Tumor and/or Sarcoma
Interventions
Liposomal Bupivacaine
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 19, 2026, 1:58 AM EDT
Active, not recruiting Phase 2 Interventional

Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

NCT02570542
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Interventions
leukapheresis, Plerixafor, carmustine, etoposide, cytarabine, melphalan, Autologous Stem Cell Transplantation
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
14
States / cities
Omaha, Nebraska • Basking Ridge, New Jersey • Middletown, New Jersey + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 19, 2026, 1:58 AM EDT
Active, not recruiting Phase 1 Interventional

NeoVax Plus Ipilimumab in Renal Cell Carcinoma

NCT02950766
View directory record Official record
Conditions
Kidney Cancer
Interventions
NeoVax, Ipilimumab
Drug
Lead sponsor
Patrick Ott, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 19, 2026, 1:58 AM EDT
Completed Phase 1 Interventional

A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma

NCT01996202
View directory record Official record
Conditions
High Risk Melanoma
Interventions
Ipilumimab, Radiation
Drug · Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years to 100 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 19, 2026, 1:58 AM EDT